Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 13/20 | 0.65 |
| ▸ | RARA | P10276 | 12/20 | 0.65 |
| ▸ | RARB | P10826 | 12/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382484 | 0.98 | RARG (0.63) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL382539 | 0.94 | RARG (0.63) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL382160 | 0.89 | RARG (0.81) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL381872 | 0.88 | RARG (0.80) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL381961 | 0.88 | RARG (0.80) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL382577 | 0.87 | RARG (0.67) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL381496 | 0.86 | RARG (0.68) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL382430 | 0.86 | RARG (0.48) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL381991 | 0.86 | RARG (0.65) | RARGRARARARBKCNH2HRH3 | |
| SCHEMBL382766 | 0.83 | RARG (0.65) | RARGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470871-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-11 | — | — | US | disclosed |
| US-8227507-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-1831149-B1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-18 | — | — | US | disclosed |
| US-7807708-B2 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | RARG 3/4885RARA 2/4885RARB 1/4885 |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | RARG 3/4885RARA 2/4885RARB 1/4885 |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | RARG 3/4885RARA 2/4885RARB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.